Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NZL9
UPID:
MAT2B_HUMAN
Alternative names:
Methionine adenosyltransferase II beta; Putative dTDP-4-keto-6-deoxy-D-glucose 4-reductase
Alternative UPACC:
Q9NZL9; B2R5Y6; Q1WAI7; Q27J92; Q3LIE8; Q567T7; Q6NYC7; Q9BS89; Q9H3E1; Q9UJ54
Background:
Methionine adenosyltransferase 2 subunit beta, also known as Methionine adenosyltransferase II beta, plays a crucial role as a regulatory subunit of S-adenosylmethionine synthetase 2. This enzyme is pivotal in catalyzing the formation of S-adenosylmethionine from methionine and ATP, with the protein enhancing MAT2A's affinity for L-methionine. Additionally, it has been shown to bind NADP in vitro, indicating a versatile function in cellular metabolism.
Therapeutic significance:
Understanding the role of Methionine adenosyltransferase 2 subunit beta could open doors to potential therapeutic strategies.